Status:
COMPLETED
A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.
Eligibility Criteria
Inclusion
- Subject has a BMI \< 42 kg/m2
- Subject is taking \>1500 mg metformin per day for at least 8 weeks
- Subject has HbA1c value of 7.0% and \< 11% at screening
- Subject is willing to follow AHA weight maintaining diet and exercise program
- Subject is a nonsmoker for at least 6 months
Exclusion
- Subject has type 1 diabetes
- Subject has a history of stroke or chronic seizure
- Subject has a history of neoplastic disease
- Subject has a history of gastrointestinal, cardiovascular, blood, liver kidney, respiratory, immunological or genitourinary disorders or diseases
- Subject is currently taking 2 or more diabetes medications
- Subject has glaucoma or is blind
- If female, subject is pregnant or breastfeeding
- Subject consumes \> 3 alcoholic beverages per day
- Subject has had major surgery or has donated blood in the last 4 weeks
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00873821
Start Date
December 1 2008
End Date
May 1 2009
Last Update
March 9 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.